IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i15p8977-d869990.html
   My bibliography  Save this article

Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status

Author

Listed:
  • Akshyaya Pradhan

    (Department of Cardiology, King George’s Medical University, Lucknow 226003, Uttar Pradesh, India)

  • Aashish Tiwari

    (Department of Cardiology, King George’s Medical University, Lucknow 226003, Uttar Pradesh, India)

  • Giuseppe Caminiti

    (Cardiology Rehabilitation Unit, S. Raffaele IRCCS, 00163 Rome, Italy)

  • Chiara Salimei

    (Department of Cardiology and CardioLab, University of Rome Tor Vergata, 00133 Rome, Italy)

  • Saverio Muscoli

    (Department of Cardiology and CardioLab, University of Rome Tor Vergata, 00133 Rome, Italy)

  • Rishi Sethi

    (Department of Cardiology, King George’s Medical University, Lucknow 226003, Uttar Pradesh, India)

  • Marco Alfonso Perrone

    (Department of Cardiology and CardioLab, University of Rome Tor Vergata, 00133 Rome, Italy)

Abstract

Dual antiplatelet therapy (DAPT) has remained the cornerstone for management of acute coronary syndrome (ACS) over the years. Clopidogrel has been the quintessential P2Y12 receptor (platelet receptor for Adenosine 5′ diphosphate) inhibitor for the past two decades. With the demonstration of unequivocal superior efficacy of prasugrel/ticagrelor over clopidogrel, guidelines now recommend these agents in priority over clopidogrel in current management of ACS. Cangrelor has revived the interest in injectable antiplatelet therapy too. Albeit the increased efficacy of these newer agents comes at the cost of increased bleeding and this becomes more of a concern when combined with aspirin. Which P2Y12i is superior over another has been intensely debated over last few years after the ISAR-REACT 5 study with inconclusive data. Three novel antiplatelet agents are already in the pipeline for ACS with all of them succeeding in phase II studies. The search for an ideal antiplatelet remains a need of the hour for optimal reduction of ischemic events in ACS.

Suggested Citation

  • Akshyaya Pradhan & Aashish Tiwari & Giuseppe Caminiti & Chiara Salimei & Saverio Muscoli & Rishi Sethi & Marco Alfonso Perrone, 2022. "Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status," IJERPH, MDPI, vol. 19(15), pages 1-18, July.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:15:p:8977-:d:869990
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/15/8977/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/15/8977/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Marco Alfonso Perrone & Alessandro Feola & Massimo Pieri & Bruno Donatucci & Chiara Salimei & Mauro Lombardo & Andrea Perrone & Attilio Parisi, 2021. "The Effects of Reduced Physical Activity on the Lipid Profile in Patients with High Cardiovascular Risk during COVID-19 Lockdown," IJERPH, MDPI, vol. 18(16), pages 1-9, August.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Stefania Scuri & Marina Tesauro & Fabio Petrelli & Ninfa Argento & Genny Damasco & Giovanni Cangelosi & Cuc Thi Thu Nguyen & Demetris Savva & Iolanda Grappasonni, 2022. "Use of an Online Platform to Evaluate the Impact of Social Distancing Measures on Psycho-Physical Well-Being in the COVID-19 Era," IJERPH, MDPI, vol. 19(11), pages 1-10, June.
    2. Lorenza Lia & Eleonora Ricci & Corrado Colaprico & Eleonora Di Legge & Augusto Faticoni & Lorenzo Maria Donini & Giuseppe La Torre, 2022. "Assessment of the Impact of COVID-19 Lockdown on the Nutritional Status and Lipid Profile of Employees in a Teaching Hospital in Rome: A Retrospective Cohort Study," IJERPH, MDPI, vol. 19(8), pages 1-12, April.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:15:p:8977-:d:869990. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.